Histamine dihydrochloride (Ceplene), by preserving the function of natural killer cells and other T-cells,
may help improve results with interferon therapy, perhaps getting the same results with smaller doses of IFN.
Maxim pharmaceuticals announced that trials with IFN + histamine dihydrochloride showed that naive hepatitis C
patients had reduced viral levels, and that 70% of those patients had undetectable viral loads, compared to 25-40% of patients on IFN alone.
Maxim has released its results from a phase II trial of IFN + Ceplene, stating that 44% of patients
receiving 10mg of Ceplene a week plus IFN had a sustained viral response at 72 weeks. Up to 50% of patients
with genotype 1 had a sustained viral response, using the highest dose of Ceplene, compared to 8% on IFN alone. P
hase II trials are about to begin with IFN + ribavirin + Ceplene in non-responders (